Detalle Publicación

ART%EF%BF%BD%EF%BF%BDCULO

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria

Autores: Kaplan, A.; Ferrer Puga, Marta; Bernstein, J.A.; Antonova, E.; Trzaskoma, B.; Raimundo, K.; Rosén, K.; Omachi, T.A.; Khalil, S.; Zazzali, J.L.
Título de la revista: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN: 0091-6749
Volumen: 137
Número: 2
Páginas: 474-81
Fecha de publicación: 2015
Resumen:
Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.
DOI: https://doi.org/10.1016/j.jaci.2015.08.023.
Impacto:
Google Scholar